Laurus Labs Limited, together with its subsidiaries, engages in the development, manufacture, and sale of medicines and active pharmaceutical ingredients (APIs) in India and internationally. The company develops, manufactures, and sells APIs and advanced intermediates for anti-retroviral (ARV), antidiabetic, cardiovascular, proton pump inhibitors (PPIs), oncology, gastroenterology, and hepatitis C therapeutic areas. It also develops and manufactures oral solid formulations for ARVs, anti-diabetic, cardiovascular, PPIs, and central nervous system. In addition, the company provides contract development and manufacturing services for pharmaceutical companies; and manufactures and sells specialty ingredients used in the nutraceutical, dietary supplements, and cosmeceutical products. Further, it develops novel enzymatic solutions for industrial biotechnology, and animal origin free recombinant proteins and enzymes for biopharma; and offers business support services for pharmaceutical field. The company was incorporated in 2005 and is based in Hyderabad, India.
P/B ratio for Laurus Labs Limited (LAURUSLABS.NS)
P/B ratio as of 2023: 5.31
According to Laurus Labs Limited's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 5.31. At the end of 2022 the company had a P/B ratio of 3.90.
P/B ratio history for Laurus Labs Limited from 2012 to 2023
P/B ratio at the end of each year
| Year | P/B ratio |
|---|---|
| 2023 | 5.31 |
| 2022 | 3.90 |
| 2021 | 9.45 |
| 2020 | 7.47 |
| 2019 | 1.96 |
| 2018 | 2.70 |
| 2017 | 3.63 |
| 2016 | 3.51 |
| 2015 | 4.54 |
| 2014 | 4.12 |
| 2013 | 8.20 |
| 2012 | 15.06 |